Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.
about
Anticoagulation for the initial treatment of venous thromboembolism in patients with cancerAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerFixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolismAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerFixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolismAntithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesLow-molecular-weight heparins in the treatment of venous thromboembolismHeparin in malignant glioma: review of preclinical studies and clinical resultsDeep Venous Thrombosis: An Interventionalist's ApproachMeasuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical reviewThe hypercoagulable state of malignancy: pathogenesis and current debateDosing and monitoring of low-molecular-weight heparins in special populations.Safety of low molecular weight heparins in the treatment of venous thromboembolism.The use of low molecular weight heparin to predict clinical outcome in patients with unstable angina that had undergone percutaneous coronary intervention.Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review.Contemporary use of and future roles for heparin in antithrombotic therapy.Danaparoid in the prevention of thromboembolic complications.Low-molecular-weight heparins in the treatment of deep-vein thrombosis.Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange.In situ crosslinkable heparin-containing poly(ethylene glycol) hydrogels for sustained anticoagulant release.A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.UK patients with deep-vein thrombosis can be safely treated as out-patients.Problems in laboratory monitoring of heparin dosage.Trends in management of phlegmasia cerulea dolens.Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009)Treatment of a patient with an undefined hypercoagulable state with long-term low-molecular-weight heparin.New developments in the prevention and treatment of venous thromboembolism.Low-molecular-weight heparins are essentially the same for treatment and prevention of venous thromboembolism.Differentiation of the low-molecular-weight heparins.A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare settingAnticoagulation in patients with thromboembolic disease.Bleeding risk during treatment of acute thrombotic events with subcutaneous LMWH compared to intravenous unfractionated heparin; a systematic review.Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism.Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacementClinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes.Declining Long-term Risk of Adverse Events after First-time Community-presenting Venous Thromboembolism: The Population-based Worcester VTE Study (1999 to 2009).Tinzaparin: considerations for use in clinical practice.Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study.
P2860
Q24193871-BA46F861-807B-4586-8F8B-8E6A641E17C8Q24234155-146FE42A-EE66-4C7F-B7E3-99FCDAFB0B2BQ24235193-48E95363-AC63-4360-B1D6-46C99F7C9A4CQ24235236-46983104-1FB1-4B94-A041-50298D85763DQ24236443-6E35C411-BDC0-4DF8-B8E1-C863DB4B2D6BQ24242243-7A1031CF-FDE7-42C8-8B9C-499A36E6C25EQ24245782-A2945D35-B505-44D8-A8D4-8E3B124ECCC2Q24633053-925A73DA-9B53-4F97-B688-54A90DD09A7EQ24792692-5F4A241E-6728-42CA-9D67-1F9B262D174FQ26821781-89501245-43C5-4645-8873-9CBC30DB0E5EQ26827598-E89730F4-6746-46AA-8C91-766A94C2C207Q26992262-8CAEFF0E-1F86-499F-9721-B9AE03E06248Q28212265-3BB77E56-97A9-4B2B-9177-1FE7E769B66FQ32049893-1AF0B929-30CA-4D52-9CB1-C3589086B036Q33349368-806A9552-6629-4535-96AB-20DE3F53AA77Q33357627-8F33D9F8-E320-4925-9B14-DC69FBC28738Q33380863-F5D49410-5048-4A20-A1C2-E6F6201D8FBDQ33495687-D8741EC2-7931-4ED4-9E3A-8602EE8536C4Q33499807-C8241495-F91D-40E2-A60B-60FBD8394310Q33502603-4E5C7493-A97A-4583-A2C0-B8ADA02D1E95Q33685447-EA69D438-ACE4-4648-AC10-52D29EE67A1BQ33894433-D4E07B08-EAFF-4A59-88B8-805BBDC5D836Q33967251-C03D819F-922F-4647-9356-09D767CF8919Q34058711-8EC61B39-B888-4335-939D-14A2F34CA9CFQ34106860-7A376BFF-9A81-45CD-852F-222A398659F4Q34157011-ECB04248-FDE5-4045-BF41-060D317842EFQ34167655-49929791-307F-413F-B89A-88C20F1877B4Q34183316-21DF3EDE-D1E8-4F88-95BC-39590A75B974Q34278849-0E2251BB-6A44-411E-9E9D-E0A01E3761C4Q34278853-77EDED50-1AC1-4495-AEF0-3810E979462AQ34278856-42E51A22-B3F3-4F70-863F-1FE1B8B52081Q34331430-D570D4CB-669D-41F3-BD71-92CCA1028925Q34342077-E971B209-18D9-4738-B83A-15DC06CC5146Q34415964-8C7AC1ED-959F-44C7-A5A6-64FA020F56A1Q34550908-D8A68725-05E9-41F9-A673-4314ABC34D86Q34708293-C5EA3123-EA50-488B-88D8-234296106C86Q35368813-7FAC97BD-B350-4E39-90D3-C686934C0714Q35559025-F065E97A-E5D2-48AE-9118-CD053428D0B4Q35591002-11951DFE-839E-40A9-A7A4-3033AAEE87D7Q35642537-255F4795-B0F4-4202-A542-9C830286F12A
P2860
Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.
description
1992 nî lūn-bûn
@nan
1992 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Subcutaneous low-molecular-wei ...... t of proximal-vein thrombosis.
@ast
Subcutaneous low-molecular-wei ...... t of proximal-vein thrombosis.
@en
Subcutaneous low-molecular-wei ...... t of proximal-vein thrombosis.
@nl
type
label
Subcutaneous low-molecular-wei ...... t of proximal-vein thrombosis.
@ast
Subcutaneous low-molecular-wei ...... t of proximal-vein thrombosis.
@en
Subcutaneous low-molecular-wei ...... t of proximal-vein thrombosis.
@nl
prefLabel
Subcutaneous low-molecular-wei ...... t of proximal-vein thrombosis.
@ast
Subcutaneous low-molecular-wei ...... t of proximal-vein thrombosis.
@en
Subcutaneous low-molecular-wei ...... t of proximal-vein thrombosis.
@nl
P2093
P1476
Subcutaneous low-molecular-wei ...... t of proximal-vein thrombosis.
@en
P2093
Brettell HR
Elliott CG
Sparling T
Trowbridge AA
P304
P356
10.1056/NEJM199204093261502
P407
P577
1992-04-01T00:00:00Z